Table 1.

Comparison between experimental humanization and our computational tool, Hu-mAb

	VH						VL
		Unadjusted (%)	Adjusted (%)	# Hu-mAb	# Experimental	Mutation (%)		Unadjusted (%)	Adjusted (%)	# Hu-mAb	# Experimental	Mutation (%)
Therapeutic	Gene	Overlap ratio	Overlap ratio	Mutations	Mutations	Ratio	Gene	Overlap ratio	Overlap ratio	Mutations	Mutations	Ratio
AntiCD28	V3	63	79	19	33	58	KV4	64	73	11	19	58
Campath	V4	75	88	16	39	41	KV1	67	67	3	14	21
Bevacizumab	V3	50	57	14	25	56	KV1	89	100	9	16	56
Herceptin	V3	59	78	27	32	84	KV1	88	88	8	22	36
Omalizumab	V3	62	76	21	34	62	KV1	89	95	19	25	76
Eculizumab	V1	73	73	15	23	65	KV1	83	83	12	20	60
Tocilizumab	V4	64	86	14	23	61	KV1	78	89	9	19	47
Pembrolizumab	V1	73	73	11	23	48	KV3	75	75	12	20	60
Pertuzumab	V3	68	79	19	32	59	KV1	80	90	10	20	50
Ixekizumab	V1	75	75	12	29	41	KV2	78	100	9	12	75
Palivizumab	V2	75	83	12	18	67	KV1	77	92	13	26	50
Certolizumab	V3	61	78	18	31	58	KV1	80	90	10	20	50
Idarucizumab	V4	80	80	15	24	63	KV2	67	67	6	8	75
Reslizumab	V3	50	80	10	21	48	KV1	83	100	6	20	30
Solanezumab	V3	50	70	10	16	63	KV2	88	100	8	10	80
Lorvotuzumab	V3	90	90	10	13	77	KV2	82	82	11	13	85
Pinatuzumab	V3	61	78	23	33	70	KV1	74	79	19	23	83
Etaracizumab	V3	58	83	12	16	75	KV3	62	69	13	25	52
Talacotuzumab	V5	78	83	18	33	55	KV4	73	73	11	16	69
Rovalpituzumab	V1	67	67	21	30	70	KV3	64	79	14	26	54
Clazakizumab	V3	86	86	7	27	26	KV1	75	75	4	22	18
Ligelizumab	V1	64	64	11	21	52	KV3	64	91	11	21	52
Crizanlizumab	V1	64	64	11	23	48	KV1	85	95	20	23	87
Mogamulizumab	V3	67	67	6	15	40	KV2	67	67	6	12	50
Refanezumab	V7	87	87	15	17	88	KV4	92	100	12	17	71
Average		68	77			59		77	85			58
Median		67	78			59		78	88			56

Note: The mutation ratio is the average number of mutations Hu-mAb suggested relative to the number of mutations made experimentally in the framework regions; Hu-mAb never suggests mutations to the CDRs. The overlap ratio is the number of mutations that were both suggested by Hu-mAb and made experimentally, relative to the number of mutations suggested by the Hu-mAb. For the ‘unadjusted’ overlap ratio, only mutations to identical amino acid types were considered; the ‘adjusted’ version considers mutations to similar amino acid types to be a match (Supplementary Table S6).